Matsuda F, Kinney W W, Wright W, Kambam J R
Department of Anesthesiology, Vanderbilt University School of Medicine, Nashville, TN 37232-2125.
Can J Anaesth. 1990 Nov;37(8):920-3. doi: 10.1007/BF03006637.
The purpose of our study was to examine the effect of intravenous (IV) nicardipine pretreatment (30 micrograms.kg-1), given three minutes before an IV bolus of bupivacaine to determine its effect on the incidence of fatal bupivacaine cardio-respiratory toxicity in adult male Sprague Dawley rats anaesthetized with intraperitoneal pentobarbital. Fifty rats were divided into four groups. Groups I and II (n = 10 each) received 3.5 mg.kg-1 0.5 per cent bupivacaine and Groups III and IV (n = 15 each) received 5.0 mg.kg-1, 0.5 per cent bupivacaine. Groups I and III received pretreatment with normal saline before bupivacaine, whereas Groups II and IV were given pretreatment with nicardipine, 30 mg.kg-1. There was no difference in the incidence of survival between the nicardipine pretreatment group and the saline placebo pretreatment group given 3.5 mg.kg-1, 0.5 per cent bupivacaine (no fatalities in either group). However, there was significant protection by nicardipine pretreatment in the group given 5 mg.kg-1, 0.5 per cent bupivacaine (13 of 15 survived, compared with only 4 of 15 in the saline pretreatment group, P less than 0.001). In conclusion, our data demonstrate that in rats given 0.5 per cent bupivacaine, 5 mg.kg-1, nicardipine pretreatment protected against fatal cardio-respiratory toxicity.
我们研究的目的是检查静脉注射（IV）尼卡地平预处理（30微克·千克-1）的效果，即在静脉推注布比卡因前三分钟给药，以确定其对成年雄性Sprague Dawley大鼠腹腔注射戊巴比妥麻醉后布比卡因致命性心肺毒性发生率的影响。50只大鼠分为四组。第一组和第二组（每组n = 10）接受3.5毫克·千克-1的0.5%布比卡因，第三组和第四组（每组n = 15）接受5.0毫克·千克-1的0.5%布比卡因。第一组和第三组在布比卡因前用生理盐水预处理，而第二组和第四组用30毫克·千克-1的尼卡地平预处理。在接受3.5毫克·千克-1的0.5%布比卡因的尼卡地平预处理组和生理盐水安慰剂预处理组之间，生存率没有差异（两组均无死亡）。然而，在接受5毫克·千克-1的0.5%布比卡因的组中，尼卡地平预处理有显著的保护作用（15只中有13只存活，而生理盐水预处理组15只中只有4只存活，P小于0.001）。总之，我们的数据表明，在给予0.5%布比卡因、5毫克·千克-1的大鼠中，尼卡地平预处理可预防致命性心肺毒性。
